Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone)  by Zheng, Suxin et al.
Chemistry & Biology
ArticleStructural Basis for Stabilization of the Tau
Pre-mRNA Splicing Regulatory Element
by Novantrone (Mitoxantrone)
Suxin Zheng,1 Yu Chen,1 Christine P. Donahue,3 Michael S. Wolfe,3 and Gabriele Varani1,2,*
1Department of Chemistry
2Department of Biochemistry
University of Washington, Seattle, WA 98195, USA
3Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
*Correspondence: varani@chem.washington.edu
DOI 10.1016/j.chembiol.2009.03.009SUMMARY
Some familial neurodegenerative diseases are asso-
ciated with mutations that destabilize a putative
stem-loop structure within an intronic region of the
taupre-messengerRNA (mRNA)andalter theproduc-
tion of tau protein isoforms by alternative splicing.
Because stabilization of the stem loop reverses the
splicing pattern associated with neurodegeneration,
small molecules that stabilize this stem loop would
provide newways todissect themechanismof neuro-
degeneration and treat tauopathies. The anticancer
drug mitoxantrone was recently identified in a high
throughput screen to stabilize the tau pre-mRNA
stem loop. Here we report the solution structure of
the tau mRNA-mitoxantrone complex, validated by
the structure-activity relationship of existingmitoxan-
trone analogs. The structure describes the molecular
basis for their interaction with RNA and provides a
rational basis to optimize the activity of this new class
of RNA-binding molecules.
INTRODUCTION
The microtubule-associated protein tau is expressed predomi-
nantly in neurons where it promotes microtubule assembly,
reduces microtubule instability, and plays a role in maintaining
neuronal integrity and axonal transport (Hirokawa, 1994). Neuro-
fibrillary lesions composed of this protein constitute a defining
neuropathological feature of Alzheimer’s disease (Spillantini
and Goedert, 1998). Filamentous tau protein deposits are also
found in other neurodegenerative diseases, many of which are
frontotemporal dementias or movement disorders that have
been subsumed under the heading of ‘‘Pick complex’’ (Kertesz
and Munoz, 1998; Spillantini and Goedert, 1998). Such neurode-
generative disorders associated with tau protein are referred to
as tauopathies (Lee et al., 2001). The tau gene consists of 16
exons that are alternatively spliced to generate six major tau iso-
forms in a developmentally regulated manner (Andreadis et al.,
1992; Goedert et al., 1989). They differ from each other by the
presence or absence of 29 or 58 amino acid inserts located inChemistry & Biology 16the amino-terminal half of the protein and a 31 amino acid repeat
located in the carboxy-terminal half. Inclusion or exclusion of the
latter by alternative splicing of exon 10 produces tau isoforms
with either three (when exon 10 is missing) or four (when exon
10 is present) microtubule-binding repeats (Goode and Fein-
stein, 1994; Gustke et al., 1994); these isoforms are known as
3R and 4R tau, respectively (Goedert et al., 1989). In the normal
adult human brain, the relative ratio of 4R to 3R tau is generally
close to unity; overproduction of 4R tau appears to be sufficient
to lead to dementia.
Mutations in the tau gene cause familial frontotemporal
dementia and parkinsonism linked to chromosome 17 (Clark
et al., 1998; Dumanchin et al., 1998; Goedert et al., 1999;
Hutton et al., 1998; Morris et al., 1999; Poorkaj et al., 1998; Spill-
antini et al., 1998). Tau mutations within coding regions cluster in
the microtubule-binding repeats and alter the ability of tau to
interact with microtubules. This occurrence initiates an unclear
set of events that lead to the formation of tau filaments in the
neurons of patients affected with a variety of neurodegenerative
diseases (Dayanandan et al., 1999; Hasegawa et al., 1998; Hong
et al., 1998). However, other mutations causing these diseases
are located within introns or are synonymous and cluster near
the splice-donor site of the intron following exon 10. Signifi-
cantly, four mutations at positions +3, +13, +14, and +16 of the
intron (with the first nucleotide of the splice-donor site taken
as +1; Figure 1A) (Goedert et al., 1999; Hutton et al., 1998; Morris
et al., 1999; Spillantini et al., 1998) are found within a putative
RNA stem loop that partially masks the splice donor itself. The
surprising discovery of these mutations led to the suggestion
that the stability of the RNA stem loop affects alternative splicing
of exon 10 and that the destabilization of the stem loop itself
alters the balance between different tau isoforms and ultimately
leads to neurodegeneration in patients carrying mutations within
this RNA structure (Hutton et al., 1998).
Several studies demonstrated that the intronic mutations found
in frontotemporal dementia and parkinsonism decrease the ther-
modynamic stability of the RNA stem loop in vitro (Donahue et al.,
2006; Hutton et al., 1998; Varani et al., 1999). It was thus postu-
lated that destabilization of this RNA structure partially unmasks
the splice site, leading to increase inclusion of exon 10 and there-
fore to increased production of the 4R tau isoform compared to
the 3R isoform (Hutton et al., 1998). More recently, Donahue
et al. (2006) have demonstrated the reverse phenomenon as, 557–566, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 557
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substantially decrease exon 10 inclusion (and therefore alter the
4R/3R ratio) in an otherwise wild-type tau minigene. Evidence
supporting the formation of the tau splicing regulatory element
(SRE) stem-loop structure in vivo was provided by the anticorre-
lation between the stability of the stem loop and the efficiency of
antisense inhibition of exon 10 inclusion (Donahue et al., 2006).
These experimental findings and the resulting model suggest
that small molecules that stabilize the tau SRE RNA stem loop
would provide very useful tools to probe the mechanism of neuro-
degeneration and perhaps new therapeutic avenues to treat
these diseases.
The aminoglycoside antibiotic neomycin, a naturally-occurring
RNA-binding molecule, was found to bind the tau SRE RNA
major groove and to stabilize the RNA structure (Varani et al.,
2000). However, this class of molecules lacks the selectivity
that would be necessary for therapeutic or even investigative
applications. A high-throughput screening assay for compounds
that bind to and stabilize the tau SRE RNA identified the anti-
cancer drug mitoxantrone (MTX) from a library of 110,000
molecules (Figure 2A) (denoted by code number LDN-13978 in
Donahue et al. [2007] and revealed as MTX for the first time
here) (Donahue et al., 2007). MTX is used in clinical practice as
a drug against breast cancer, acute leukemia, and non-Hodg-
kin’s lymphoma (Hagemeister et al., 2005; Tsavaris et al.,
2005); it has also been approved in the U.S. for the treatment
of patients with progressive multiple sclerosis (Gonsette,
2003). The lead-like activity of MTX in binding to the tau SRE
(EC50 of 700 nM) and its current multiple uses in clinical prac-
tice makes it an attractive lead to discover new small molecule
regulators of tau messenger RNA (mRNA) splicing, but its activity
must first be improved.
Here we report the nuclear magnetic resonance (NMR) struc-
ture of the complex between MTX and the region of SRE that
constitutes the defining structural characteristic of this RNA.
MTX intercalates into the partially open bulge region of tau
Figure 1. Sequences of Wild-Type and
Mutant Tau SREs
(A) Sequences and secondary structures of wild-
type and mutant human tau exon 10 SREs. Desta-
bilizing mutations at the +3, +13, +14, and +16 (in
red) positions is linked to familial neurodegenera-
tive diseases and increases inclusion of exon 10
(Goedert et al., 1999; Hutton et al., 1998; Morris
et al., 1999; Spillantini et al., 1998). In contrast,
stabilizing mutations at +10 and the I17T insertion
(in blue) decreases inclusion of exon 10 in vitro
(Donahue et al., 2006).
(B) The sequence of the wild-type tau SRE con-
taining nucleotides G5 to C+19 used in our
NMR structural studies.
SRE RNA with the side chains forming
sequence-specific hydrogen bonds with
the nearby RNA bases and electrostatic
interactions with the phosphate back-
bone. The structure explains the struc-
ture-activity relationship (SAR) of a series
of MTX analogs and provides the struc-
tural basis for the design of more potent and specific regulators
of tau pre-mRNA splicing.
RESULTS
Formation and Stoichiometry of the MTX-Tau
RNA Complex
In order to characterize the MTX-RNA complex, we titrated tau
SRE RNA with MTX at concentrations suitable for NMR investi-
gations (0.1–1 mM) and recorded spectra for the imino proton
region, where the RNA resonances corresponding to Watson-
Crick paired nucleotides are well resolved (Figure 2B). From
the bottom, the spectra correspond to MTX/RNA ratios of 0.0,
0.5, 1.0, 1.5, 2.0, and 3.0. The chemical shifts of the imino reso-
nances in the upper helical region (G+1, U+2, and G+3) were
not changed, but only broadened during the titration. For reso-
nances near the bulge loop (G1 and U0), we observed a
decrease in the intensity of the peak corresponding to the free
RNA signal as the MTX concentration increases; at the same
time, a new set of peaks appeared at distinct positions that
were later assigned to the MTX-bound form of the RNA. The
peaks corresponding to the free form of the RNA disappear
completely only when the ratio of MTX/RNA is >2.0 (Figure 2B).
Multiple sets of imino resonances appear when the ratio of
MTX/RNA is larger than 1.5; these new peaks must arise from
the binding of multiple copies of MTX to the RNA when more
than one molecule of MTX per RNA is present. The observation
of distinct peaks in slow exchange on the NMR time scale
corresponding to free and bound RNA indicates that MTX binds
tightly (Kd < 1 mM) at or near the RNA bulge region, which is
consistent with an EC50 of about 700 nM previously reported
(Donahue et al., 2007).
The observation of two peaks with comparable intensity corre-
sponding to the free and bound RNA resonances at MTX/RNA
ratios of about 1 (see, e.g., U0; Figure 2B) has two possible
explanations. MTX could bind as a dimer or it could form more558 Chemistry & Biology 16, 557–566, May 29, 2009 ª2009 Elsevier Ltd All rights reserved
Chemistry & Biology
Small Molecule-Recognized Tau Pre-mRNA Splice Sitethan one independent interaction with the RNA. The observation
of additional peaks in the 1D spectra at ratios above 1:1 strongly
suggests that when there are two binding sites, an additional
MTX molecule binds with comparable affinity to a second site
within the RNA. On the other hand, the reported self-association
constant (12400 ± 4000 L mol1) of MTX in aqueous solutions
(Davies et al., 2001) and the 1D titration experiment show that
MTX should be dimeric at NMR concentrations.
We confirmed the dimeric form of free MTX in solution by
observing intermolecular nuclear Overhauser effects (NOEs)
between the H2/3 resonances of one MTX and the H6/7 reso-
nances as well as the side chain resonances (H11/15 and H12/
16) of a second copy of the molecule (Davies et al., 2001). These
NOE interactions are only possible if the two MTX molecules are
arranged in a reversed stacking conformation sitting on each
other in a head-to-tail orientation. However, in the 2D NOESY
spectra of the complex, we failed to observe any intermolecular
NOEs involving two MTX molecules between the H2/3 and H6/7
of MTXs; we also failed to observe NOEs between the H2/3
aromatic resonances and the same side chain resonances
Figure 2. Structure of MTX and Spectra of
NMR titration of Tau SRE RNA
(A) Structure of MTX.
(B) NMR titration of tau SRE RNA with increasing
concentrations of MTX recorded at 4C. From
the bottom, spectra correspond to the following
ratios of MTX/RNA: 0.0, 0.5, 1.0, 1.5, 2.0, and
3.0. The label in the bottom spectrum corresponds
to the assignments for the free RNA, whereas the
top label corresponds to the MTX-bound RNA.
(H11/15 and H12/16) that were observed
instead for free MTX. All these NOEs
would be expected for a dimeric structure
and indeed were observed for the free
MTX dimer. As a control, we readily
observed NOEs between the H6/7 reso-
nances and the side chain H11/15 and
H12/16 in the RNA complex; in fact, these
NOEs were much stronger compared to
the free MTX dimeric structure, most
likely because the conformation of the
side chain is rigidified in the complex
(see below), leading to more efficient
NOE transfer. If MTX bound to RNA as
a dimer, we would expect to see much
stronger NOEs than we observe in
the RNA-free MTX dimer between the
aromatic H2/3 and H6/7, as well as the
side chain H11/15 and H12/16 reso-
nances. Altogether, these results are
inconsistent with the binding of MTX as
an antiparallel dimer to the tau SRE
RNA. Although it is possible that MTX
dimerizes, forming a parallel stacking
arrangement (in this case, intra- and inter-
molecular NOEs would be very difficult
to distinguish), this is highly unlikely
because of the resulting electrostatic repulsion. Thus, the titra-
tion experiments are better explained by a model where multiple
molecules of MTX bind to different locations on the RNA.
Consistent with the conclusion that two MTX molecules bind
to the SRE RNA in distinct locations, we observed two distinct
sets of intermolecular NOEs when analyzing NOESY spectra. A
more numerous and more intense set of intermolecular contacts
mapped to the RNA bulge; a second, much less numerous, set
corresponded to the minor groove near the upper helix. Binding
of MTX to the minor groove of the RNA does not lead to signifi-
cant chemical shift changes in the RNA, suggesting that this
interaction is only superficial and perhaps corresponds to the
nonspecific electrostatic interactions between the highly
cationic MTX and the negatively charged phosphate backbone.
The binding sites of MTX on tau SRE RNA was mapped by
chemical shift perturbation analysis as well (see Tables S1 and
S2 available online). Modest chemical shift changes were
observed in the upper stem loop, never larger than 0.12 ppm,
where the NOE data indicate that a second molecule of MTX
binds. Much more significant chemical shift changes wereChemistry & Biology 16, 557–566, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 559
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for the H8 of A2 is 0.16 ppm; the imino resonance of G+17 was
not observed in the free form due to exchange with solvent, but
readily observed in the complex with MTX. The largest chemical
shift change is observed for the imino of G1 (0.62 ppm). The
observation of the G+17 imino in the complex, but not in the
free form, indicates that this resonance is shielded from solvent
in the complex either because the bulge region is stabilized by
the binding of MTX, because MTX itself shields this hydrogen,
or both. Thus, all available NMR results are consistent with the
conclusion that MTX binds to tau SRE RNA in two locations. A
first site corresponds to the region near the bulge; binding of
MTX here induces significant chemical shift changes, indicating
an intimate interaction, and is likely responsible for the stabiliza-
tion of the stem loop. A second complex forms in the minor
groove close to the upper helical region; this second complex
does not induce large conformational and chemical shift
changes in the RNA.
To further establish the physical chemical characteristics of
the anthraquinone chromophore in the complex, we used UV/
Vis and fluorescence spectroscopy. The experiment differs
from the NMR titration because RNA is now titrated into a fixed
amount of MTX (10 mM) and not the reverse. The maxima in
absorbance of free MTX were located at 608.4 and 659.4 nm
(Figure 3). In the first stage of the titration (RNA/MTX < 0.1), the
intensities of these two absorbance peaks decreased sharply;
in the second stage, the intensities of the two new peaks (626
and 681 nm; Figure 3) increased gradually until saturation was
reached at an RNA/MTX ratio R1.0. Both absorption peaks
shift to the red by about 18 and 22 nm, respectively; such bath-
ochromic effects are commonly observed for DNA intercalators
(Li et al., 2005). Comparable bathochromic effects were also
observed in fluorescence titration experiments (Figure S1). The
UV/Vis and fluorescence data indicates that MTX binds to tau
SRE RNA by partially intercalating or at least forming clear
stacking interaction with base ring systems. The two-stage
binding mode (first, the free MTX intensity decrease quickly;
second, the bound MTX absorption increases gradually)
suggests that there are multiple MTX binding sites. The sharp
initial decrease in absorbance may be due to RNA condensation
Figure 3. Titration of Tau SRE RNA with
MTX Monitored by UV/Vis Spectroscopy
The experiments were carried out in buffer solution
(10 mM; pH 6.0) containing 10 mM MTX in the pres-
ence of different RNA concentrations. RNA/MTX
are as follows: 0.0 (a); 0.02 (b); 0.05 (c); 0.1 (d);
0.2 (e); 0.5 (f); 1.0 (g). The absorbance was satu-
rated after the ratio of RNA/MTX reached 1.0.
caused by charge interactions when
multiple MTX molecules, each with two
positive charges, bind to one RNA
molecule and neutralize the negative
charges in the phosphate backbone
(Kapuscinski and Darzynkiewicz, 1984,
1986). In the second stage, as the titration
continues, MTX molecules redistribute
among increasing amounts of available
free RNAs, until eventually most find their preferred binding sites
are saturated.
The NMR results indicate that there are multiple binding sites
for MTX on the RNA. Sharp NMR spectra were obtained at MTX/
RNA ratios near 1.0. Under this condition, we observed two sets
of resonances near the lower bulge corresponding to the free
and bound forms of the RNA, with comparable intensities.
Despite the increased complexity in the spectra at 1:1 ratio,
the signals corresponding to bound and free components can
be distinguished unambiguously at high field (Figures S3 and
S4), particularly when using partially deuterated nucleotides or
13C/15N-labeled RNA in 3D spectra. Increasing the MTX/RNA
ratio (e.g., at ratios of 1.5:1 and 2:1) to saturate binding at the
bulge caused considerable broadening in the aromatic and
ribose regions of the NMR spectrum, presumably due to confor-
mational exchange involving the other weaker sites (e.g., the site
near the apical loop). Furthermore, there are not sufficient
intermolecular NOEs to define the minor groove binding confor-
mation. Thus, we chose the 1:1 ratio as the best condition to
determine the structure of the complex; under these conditions,
we could only study the most favorable and specific binding site
on tau SRE near the bulge immediately adjacent to the splice
junction.
NMR Spectral Assignments
Spectral assignments were obtained in a straightforward manner
starting from the available assignments for the free RNA
(Figure S2). Some assignments were obtained by observing
exchange peaks near the diagonal, others simply by following
the conventional procedures that connected both the free and
bound RNA peaks (in the MTX binding site) to a single set of
peaks corresponding to resonances that do not shift in the
complex (Figures S3 and S4). Assignments are reported in Table
S1. Critical to structure determination was the observation of
intermolecular NOEs between the MTX side chains and RNA
resonances; some are shown in the 2D NOESY spectrum of
Figure 4A; their complete list is reported in Table S4. At 25C,
we observed numerous intermolecular NOEs between MTX
side chains and the RNA, but none was observed with the
MTX ring H2/3 resonances. As a result, the location of the560 Chemistry & Biology 16, 557–566, May 29, 2009 ª2009 Elsevier Ltd All rights reserved
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be defined unambiguously.
The data at 25C are consistent both with the chromophore
being inserted into the bulge region and stacked on the RNA
bases and with the chromophore pointing away from the bulge
region with only the MTX side chains interacting with the RNA.
We deemed this second conformation unrealistic because of
the results of the UV/VIS experiments that suggest partial inter-
calative binding and because it would expose the hydrophobic
chromophore to solvent. However, we sought to establish the
correctness of the first conformation unambiguously. Although
the peaks become broader at lower temperature, the NOESY
spectra could still be assigned at 4C with the help of partially
Figure 4. Two-Dimensional NOESY Experi-
ment Recorded at 4C on the Complex
between MTX and Tau SRE RNA
(A) Regions of the spectrum corresponding to
intra- (MTX) and intermolecular (MTX and RNA)
NOEs are boxed and labeled.
(B) The intermolecular NOE observed for G+17H1’
and MTXH2/3. ‘‘b’’ refers to the bound com-
ponent. For example, H13-G+17bH8 refers to
the NOE between the MTXH13 and the G+17-
bound H8.
deuterated RNA (that decreases the line-
width due to less efficient relaxation) and
of 13C/15N-labeled RNA. At 4C, we
observed key intermolecular NOEs
between MTX H2/3 and the H1’ of G+17
(Figure 4B), which indicates that MTX
was stacked on the base of G+17,
consistent with the most likely of the two
conformations described above.
Structure of the Complex between
MTX and Tau SRE RNA
Structure calculations were carried out
using NIH-Xplor and standard protocols
(Clore and Kuszewski, 2003) using a total
of 41 intermolecular NOEs (Table S4).
From 100 calculated structures, the top
20 were chosen to represent the
ensemble of conformations based on
their energy and restraint violation statis-
tics. Statistics of data collection and for
the converged structure are shown in
Table 1. The superposition of the ten
best structures (Figure 5A) shows the
helical stem and bulge where MTX binds
are very well defined, but the apical
loop remains conformationally flexible.
The anthraquinone chromophore of MTX
stacks on the base of G+17, consistent
with the large chemical shift change for
its NH, while the positively charged side
chains interact with the major groove of
the RNA; the unpaired A2 nucleotide
protrudes outward into solution (Figure 5B). The length and
helical axis of the RNA in the complex were almost unaltered
compared to the free RNA structure (Varani et al., 1999).
Close-up views of the interaction between MTX and RNA
taken from the best-scoring structure are shown in Figure 5C.
Consistent with the UV/VIS results and the protection of the
G+17 imino from exchange with solvent, the chromophore of
MTX is stacked between the base pairs of G+17–C3 and
C+16–G1, forming partial stacking interaction with both base
pairs. This interaction may be the dominant driving force for
the formation of the complex. In addition, a well ordered network
of hydrogen bonds and electrostatic contacts is observed
between the MTX side chains and tau SRE RNA. The distancesChemistry & Biology 16, 557–566, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 561
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shown in Table S5. These additional interactions increase both
the affinity of MTX binding and presumably the stability of the
tau SRE RNA structure (Donahue et al., 2007). Although the pre-
dicted pKa (http://ibmlc2.chem.uga.edu/sparc/) showed that
the two amines (N3 and N4) should be protonated at the exper-
imental pH (pH 6), we did not include any specific electrostatic
term during structure calculation or refinement to avoid intro-
ducing any unintended bias in the structure determination
process. Thus, the additional electrostatic and hydrogen-
bonding interactions observed in the complex, such as the elec-
trostatic interaction between N4 of MTX and phosphate of G+17
and hydrogen bond between O6 of MTX and O4 of U+18
(Figure 5C), are derived from the experimental intermolecular
NOE constraints (Table S4), although not directly verified from
experimental data (such as RNA-MTX scalar couplings).
In the complex, the N3 and N4 amines in the MTX side chains
form hydrogen bonds with the O6 of the G1 and N7 of G+17
bases, respectively (Figure 5C). The MTX N4 amine can form
hydrogen bonds with the base of G+17 and at the same time elec-
trostatic contacts with the phosphate of G+17. One hydroxyl
group (O6) of MTX is in hydrogen-bonding contact with the O4
of U+18, while another hydroxyl group (O5) is hydrogen bonded
with the phosphate of G1. Although the hydrogen bond between
the imino N2 group and the phosphate of C+16 is not likely to
provide specificity for a particular RNA sequence, the hydrogen
bond between the imino group N1 and O6 of G1 is specific for
the G1 base. The two hydroxyl groups in the chromophore can
also form hydrogen bonds with the O2’ of C+16 and A2, as sup-
Table 1. Experimental Constraints and Structure Statistics
Experimental constraints
RNA-RNA distance constraints 516
RNA-MTX distance constraints 41
Hydrogen-bonding constraints 51
Base-pair planarity restraints 18
Dihedral constraints 173
Dipolar couplings 30
Total experimental constraints 829
Average RMS deviations from experimental restraintsa
Distance 0.04 A˚
Dihedral 0.85
RDC 0.53 Hz
Average RMS deviations from ideal geometriesa
Bonds 0.0034 A˚
Angles 0.78
Impropers 0.40
RMS deviation from average structurea (heavy atom)
Full structure 2.33 ± 0.61 A˚
Double helical stem (G1–A+4; U+11–C+16) 0.77 ± 0.40 A˚
MTX binding site (G4–U0; A+15–U+18) 1.02 ± 0.43 A˚
MTX 0.74 ± 0.32 A˚
Standard deviation is used for the error bars.
a The top 20 out of 100 calculated structures were selected as converged
structures.562 Chemistry & Biology 16, 557–566, May 29, 2009 ª2009 Elsevierported by weak NOE interaction with A2, providing selectivity
over DNA and a distinct mode of binding. Although the intercala-
tion of the anthraquinone chromophore into RNA is not believed to
besequencespecific, thehydrogenbondsbetween the side chain
N3/4 of MTX and the G1 and G+17 bases can provide specificity
for adjacent GC base pairs in a structural context permissive to
binding, as generated by the bulged A2 nucleotide.
SAR for MTX Analogs
To explore the SAR of MTX binding to tau SRE RNA, a series of
MTX analogs (Table 2) were obtained from the National Cancer
Institute and tested for their ability to stabilize the tau RNA
stem loop, using a fluorescence resonance energy transfer
assay that uses a tau RNA oligonucleotide with a fluorophore
on the 30 end and a quencher on the 50 end of the stem loop
(Donahue et al., 2007). Satisfactorily, the NMR structure of the
complex is for the most part consistent with the results of Table
2. In the structure, the hydrophilic groups of MTX (O1/2, O5/6,
and N3/4) are involved in a well defined hydrogen-bonding
network, as described above. All observable activity is elimi-
nated when these hydrophilic groups are substituted with
nonpolar groups (compound 4 in Table 2). The N3/4 amine
groups form hydrogen bonds with the guanine bases from the
two GC base pairs abetting the unpaired A2 nucleotide. Even
a change in the N3/4 amine to ether groups, as in 1, leads to
a >70-fold decrease in the EC50. The O1/2 hydroxyl groups
involved in hydrogen bonds with the hydroxyl O20 of C+16 and
A2 contribute less to RNA binding, because their substitution
to hydrogen only reduces the EC50 about six times (3). To our
surprise, modifying the O5/6 hydroxyl groups to the better
hydrogen-bonding donor amines (2) did not increase binding,
but instead decreased the EC50 more than 7000 times.
DISCUSSION
Modulating RNA with small molecule drugs would provide the
opportunity to regulate the function of RNA in chronic and infec-
tious disease conditions (Thomas and Hergenrother, 2008). An
inviting target for small molecules that bind to RNA is the SRE
within the tau pre-mRNA that controls the ratio of the two major
tau protein isoforms. Mutations that destabilize the tau stem-
loop structure increase inclusion of exon 10 and are associated
with neurodegenerative tauopathies. Since mutations that stabi-
lize the RNA can reduce exon 10 inclusion, stabilization of the
stem loop with a small molecule would also reduce exon 10 inclu-
sion. Thus, if we were able to regulate alternative splicing of tau
exon 10, we would be better able to define its precise role in
a variety of neurodegenerative disease conditions and perhaps
explore new therapeutic options as well.
Unfortunately, there is no precedent for the successful clinical
or even preclinical development of RNA-binding small molecules
outside of the ribosome, a mainstay target of antibacterial treat-
ment. Among well known antibacterials targeting the ribosome
are aminoglycoside antibiotics such as neomycin. In a previous
study, we showed that this drug binds in the major groove of
the tau SRE RNA. However, these molecules have poor speci-
ficity and are synthetically challenging; they have been proven
to be unattractive leads to the development of new RNA-binding
drugs because of the lack of selectivity that would be necessaryLtd All rights reserved
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(A) Superposition of the ten best calculated structures (heavy atoms only) represented with MOLMOL (Koradi et al., 1996). The RNA is shown in blue and MTX is
shown in red.
(B) The best calculated structure. MTX is shown in yellow stick representation and the RNA backbone is shown in brown with Pymol (DeLano, 2002).
(C) Close-up view of the tau SRE RNA-MTX interaction. The carbon atoms of MTX are shown in yellow and the RNA in green with Pymol (DeLano, 2002); some key
intermolecular NOEs between the H1’ of G+17 and H2/3 of MTX are shown by blue dashed lines.for therapeutic efficacy. In the search for new small molecules
that interfere with tau pre-mRNA splicing, the anticancer drug
MTX was found to bind to the tau SRE and stabilize its structure
in a screen of over 100,000 molecules (Donahue et al., 2007).
Here we report the structure of its complex with tau SRE RNA
and a molecular rationale for its binding activity.
The activity of MTX as an anticancer drug has led to some
interest in understanding the molecular basis of its interaction
with DNA, but so far these studies have been based on molecular
modeling (Islam et al., 1985; Kostjukov et al., 2007) and not
a formal structure. In addition to providing a structural basis to
further optimizing the affinity and specificity of MTX for tau pre-
mRNA stem-loop structure, the present structure also sheds
more insight into the general mechanism of the interaction of
MTX with nucleic acids in general.
MTX binds the bulge region of tau SRE RNA by partially inter-
calating in the space created by the extruded base A2 and by
forming hydrogen bonds to two adjacent GC base pairs (G1–
C+16 and G+17–C3) and one uracil residue (U+18) nearby
that are specific to these bases. Although free MTX self-associ-
ates, forming a dimer, a variety of spectroscopic observations
indicate that MTX binds to tau SRE RNA as a monomer and
has a second, slightly weaker binding site in the minor groove
of the RNA near the apical stem loop. The second binding site
is most probably due to superficial electrostatic interactions
between the positively charged MTX and the RNA backbone,Chemistry & Biology 16because chemical shift changes in the RNA upon binding are
very small. In contrast to the main complex near the bulge, we
cannot establish this second binding conformation due to the
paucity of intermolecular NOEs observed for it.
Table 2. SAR for MTX Analogs
Compound X Y Z EC50 (mM)
MTX OH NH OH 0.72
1 OH O OH >50
2 OH NH NH2 >5000
3 H NH OH 4.3
4 H CH2 CH3 NA, 557–566, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 563
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contacts with the RNA do not lead to sequence-specific binding,
but require nonetheless a specific structure, a bulged nucleotide.
Moreover, the hydrogen bonds between the MTX side chain
amine N3/4 and the base O6 carbonyls of G1 and N7 of
G+17 suggest that MTX prefers to recognize GC base pairs
(G1–C+16 and C3–G+17). Although these interactions are
clearly sequence specific, the flexibility of the side chains allows
the positions of the hydrogen-bonding groups to adapt them-
selves to other RNA sequences and bind to them with compa-
rable effectiveness. However, the structure suggests that by
rigidifying these amines in a more constrained structure, it should
be possible to optimize hydrogen-bonding interactions between
MTX and the GC base pairs and thereby generate MTX deriva-
tives that are specific for the tau SRE structure.
In addition to the side chain amines, the hydroxyl group O6 of
MTX is in hydrogen-bonding contact with the O4 of U+18, a result
well established by one of the strongest intermolecular NOEs
observed between the H18 of MTX and the H5 of U+18. This
hydrogen-bonding interaction also contributes to the specific
recognition of U+18. Therefore, the length of the MTX side chain
between O6 and the chromophore may be varied to enforce
stronger hydrogen bonds with U+18 to select against other
RNAs. We plan to exploit these suggestions in future studies to
improve the binding characteristics of MTX derivatives with the
tau stem loop and to generate MTX variants that selectively
bind to this structure.
SIGNIFICANCE
Modulating RNA structure with small molecule drugs would
provide the opportunity to regulate the function of RNA in
chronic and infectious disease conditions. An inviting target
for small molecules that bind to RNA is the SRE within the
tau pre-mRNA that controls the ratio of the two major tau
protein isoforms. Mutations that destabilize the tau SRE
RNA increase inclusion of exon 10 into the mature tau
protein and are associated with neurodegenerative tauopa-
thies. Sincemutations that stabilize the RNA reduce exon 10
inclusion, stabilization of the stem loopwith small molecules
would also reduce exon 10 inclusion and provide a new way
to define its precise role in a variety of neurodegenerative
disease conditions and to explore new therapeutic options.
The anticancer drug MTX was recently identified in a high-
throughput screen to stabilize the tau SRE RNA. Here, we
report the structure of tau pre-mRNA in complex with MTX
at the bulge region, which identifies a new class of RNA-
small molecule interactions. This structure provides a basis
to optimize the potency and specificity of MTX analogs and
sheds light into the general mechanism of the interaction of
MTX with nucleic acids.
EXPERIMENTAL PROCEDURES
RNA Preparation
A model oligonucleotide mimic of the wild-type tau SRE containing nucleo-
tides from G5 to C+19 (Figure 1B) was used in all experiments. RNA oligonu-
cleotides were synthesized by in vitro transcription using T7 polymerase and
synthetic DNA templates (IDT) with commercially available unlabeled, selec-
tively deuterated, and 13C/15N-labeled nucleotides (Cambridge Isotope Inc.).564 Chemistry & Biology 16, 557–566, May 29, 2009 ª2009 ElsevieThe selectively deuterated nucleotides were used to simplify the NMR spectra
by only containing H2/H6/H8 and H10/200 resonances; all other positions were
deuterated. All RNA samples were purified as described (Price et al., 1998).
Microdialysis was used to bring the final buffer to 10 mM sodium-phosphate
(pH 6.0) with 0.1 mM EDTA. Lyophilized RNAs were redissolved in 5% D2O/
95% H2O or 100% D2O as needed. Samples used for residual dipolar coupling
(RDC) measurements were mixed with Pf1 phage (ASLA Ltd) and dialyzed
against the same buffer at a final phage concentration of 12–15 mg/ml. MTX
(>97%) was purchased from Sigma and used without further purification.
Data Collection and Analysis
Most NMR data were acquired on Bruker 500 MHz and 600 MHz Avance spec-
trometers equipped with cryoprobes and a 750 MHz DMX spectrometer
equipped with a conventional HCN probe. The D2O NOESY on the complex
was collected at Pacific Northwest National Laboratory on a Varian 800 MHz
spectrometer equipped with a cryoprobe. In-Phase-Anti-Phase HSQC spectra
(Andersson et al., 1998) for RDC measurements were collected at 500 MHz.
Data were processed with nmrPipe (Delaglio et al., 1995) and analyzed with
Sparky (Goddard and Kneller, 2008). The spectra for the H2O sample were
recorded at 4C and those for the spectra in D2O were recorded both at
25C and 4C.
The assignments for the complex were initiated by standard 2D NOESY walks
that were extended from the part of the structure that did not change upon
binding to MTX into the section where changes were observed (see also Figures
S2 and S3); the assignments were facilitated by 3D NOESY-HSQC experiments
due to the fact that 13C shifts did not change considerably upon MTX binding
(Varani et al., 1996). The bound resonances were further confirmed by
observing exchange peaks in 2D NOESY spectra (Figure S3); the partial deuter-
ated sample was used to reduce the overlap in the ribose region (Figure S4). The
complete proton assignments of free and bound tau SRE RNA are listed in Table
S1 and the assignments of MTX are listed in Table S3. Base pairs were estab-
lished from the imino peaks observed in 2D water NOESY collected with Water-
gate water suppression (Dingley and Grzesiek, 1998; Pervushin et al., 1998).
Dihedral angle restraints were obtained from 2D TOCSY experiments, as
described (Varani et al., 1996), and the C20-endo constraints for the sugar
pucker were used only when both H1’/H2’ and H1’/H3’ coupling were large.
Structure Calculations
NOEs involving nonexchangeable protons were classified as strong (1.8–3.2 A˚),
medium (2.2–4.2 A˚), weak (2.5–5.5 A˚), or very weak (3.0–7.0 A˚) based on
cross-peak intensities at 100 and 200 ms mixing times (2D NOESY experi-
ments) and 120 ms (3D NOESY-HSQC). NOEs involving exchangeable protons
were characterized as strong (1.8–3.4 A˚), medium (1.8–4.5 A˚), weak (1.8–6.0 A˚),
and very weak (1.8–6.5 A˚) based on their NOE cross-peak intensities at 100 and
200 ms mixing times (Chen et al., 2006).
A single extended starting structure was generated with Xplor-NIH (Schwi-
eters et al., 2003) and the structure calculations were carried out by Xplor-NIH
with the same strategy by using the means of conformational database poten-
tial (Clore and Kuszewski, 2003). RDC-derived restraints were added only after
the majority of converged structures were found and only RDCs obtained from
well ordered residues devoid of conformational exchange were used in refine-
ment (Leeper and Varani, 2005).
Optical Spectroscopy Studies
UV/Vis absorbance spectra were obtained on a Beckman DU-650 spectropho-
tometer equipped with a quartz micro-colorimetric vessel of 1 cm path length.
Activity Measurement of MTX Analogs
MTX analogs were obtained from the National Cancer Institute and were
tested for their ability to stabilize the tau RNA stem-loop structure using a fluo-
rescence resonance energy transfer assay as previously described (Donahue
et al., 2007) in which the 50 end of the tau RNA oligomer is linked to dabsyl and
the 30 end is linked to fluorescein.
ACCESSION NUMBERS
Coordinates have been deposited in Protein Data Bank with accession code
2kgp.r Ltd All rights reserved
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